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Abstract
Aims: Radiotherapy target volumes in early breast cancer treatment increasingly include the internal mammary chain (IMC). In order to maximise survival
beneﬁts of IMC radiotherapy, doses to the heart and lung should be minimised. This dosimetry study compared the ability of three-dimensional conformal
radiotherapy, arc therapy and proton beam therapy (PBT) techniques with and without breath-hold to achieve target volume constraints while minimising dose
to organs at risk (OARs).
Materials and methods: In 14 patients’ datasets, seven IMC radiotherapy techniques were compared: wide tangent (WT) three-dimensional conformal
radiotherapy, volumetric-modulated arc therapy (VMAT) and PBT, each in voluntary deep inspiratory breath-hold (vDIBH) and free breathing (FB), and
tomotherapy in FB only. Target volume coverage and OAR doses were measured for each technique. These were compared using a one-way ANOVA with all
pairwise comparisons tested using Bonferroni’s multiple comparisons test, with adjusted P-values  0.05 indicating statistical signiﬁcance.
Results: One hundred per cent of WT(vDIBH), 43% of WT(FB), 100% of VMAT(vDIBH), 86% of VMAT(FB), 100% of tomotherapy FB and 100% of PBT plans in vDIBH
and FB passed all mandatory constraints. However, coverage of the IMC with 90% of the prescribed dose was signiﬁcantly better than all other techniques using
VMAT(vDIBH), PBT(vDIBH) and PBT(FB) (mean IMC coverage  1 standard deviation ¼ 96.0%  4.3, 99.8%  0.3 and 99.0%  0.2, respectively). The mean heart
dose was signiﬁcantly reduced in vDIBH compared with FB for both the WT (P < 0.0001) and VMAT (P < 0.0001) techniques. There was no advantage in target
volume coverage or OAR doses for PBT(vDIBH) compared with PBT(FB).
Conclusions: Simple WT radiotherapy delivered in vDIBH achieves satisfactory coverage of the IMC while meeting heart and lung dose constraints. However,
where higher isodose coverage is required, VMAT(vDIBH) is the optimal photon technique. The lowest OAR doses are achieved by PBT, in which the use of vDIBH
does not improve dose statistics.
Crown Copyright  2018 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The 2014 Early Breast Cancer Trialists’ Collaborative
Group systematic overview reported a signiﬁcant reduction
in breast cancer mortality associated with post-mastectomy
locoregional breast radiotherapy irrespective of the number
of lymph nodes involved and systemic therapies used [1].al College of Radiologists. This is an open access article under the CC BY-NC-ND
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wall locoregional lymph node radiotherapy (including the
internal mammary chain [IMC]) reported disease-free sur-
vival beneﬁts in the locoregional lymph node radiotherapy
group [2,3]. Subsequently, the Danish Breast Cancer Group
IMC study, which compared outcomes in right breast-
affected patients (who had the IMC irradiated) versus left
breast-affected patients (who did not have the IMC irradi-
ated), showed an overall survival beneﬁt for IMC irradiation
of 4.4% in all node-positive patients and 7.4% in those pa-
tients with amedial or central tumour and/or a minimum of
four positive lymph nodes [4]. Following publication of
these data, the UK Royal College of Radiologists issued
guidance that IMC irradiation should be considered in pa-
tients at higher risk of locoregional recurrence [5].
In long-term breast cancer survivors treated with
radiotherapy, fatal radiation-induced heart disease is the
main competing cause of mortality. Standard radiotherapy
techniques to treat the IMC (using wide tangents [WT] with
matched photon-electron ﬁelds in free breathing [FB]) have
previously been shown to deliver mean heart doses (MHD)
of around 9 Gy [6]. A caseecontrol study suggested that the
rate of radiation-induced major coronary events increases
linearly with dose (7.4%/Gy) and that there is no apparent
threshold below which patients are safe [7e9]. Therefore,
reducing the heart dose in patients undergoing IMC radio-
therapy is of vital importance.
Technical solutions exist for reducing the heart dose
associated with breast cancer radiotherapy. The UK Heart-
Spare IA trial showed that a simple and cost-effective
voluntary breath-hold technique (voluntary deep inspira-
tory breath-hold; vDIBH) could at least halve MHD from
2 Gy to <1 Gy in the context of breast/chest wall radio-
therapy alone [10]. Intensity-modulated radiotherapy,
volumetric-modulated arc therapy (VMAT) and proton
beam therapy (PBT) can also reduce heart doses, but
limiting heart doses cannot be achieved in isolation [11e15].
For locoregional pan-lymph node treatments, where the
target volume envelops the thorax, multi-ﬁeld photon
beam arrangements can increase low doses to the organs at
risk (OAR), potentially increasing the risk of radiation-
induced heart disease and secondary cancers [16e18]. PBT
has been shown in dosimetry studies to deliver lower car-
diac doses compared with photon-based techniques
[11,12,14], but the additional beneﬁt of breath-hold to PBT
has been less well studied.
The aim of this study was to compare target volume
coverage and OAR doses using seven radiotherapy tech-
niques in order to establish optimal solutions for imple-
mentation in UK IMC radiotherapy practice.Materials and Methods
Patient Selection and Volume Delineation
Fourteen patients from a single centre with left-sided
breast cancer who had been previously treated within the
HeartSpare II trial [19] (by virtue of having any heart withinthe 50% isodose on the FB computed tomography planning
scan) were selected. The patients’ median age was 57 years
(range 31e68 years). Ten patients had undergone wide local
excision, one mastectomy and three mastectomies with
deep inferior epigastric perforators ﬂap reconstruction. All
patients had undergone two radiotherapy planning
computed tomography scans, one in FB and one in vDIBH.
Left-sided clinical target volumes ([CTVs] breast, axillary
levels 1e4 and IMC) were delineated by a panel of four
clinical oncologists based on ESTRO guidelines [20]. The
planning target volumes (PTVs) were constructed by adding
a 5 mm margin to the CTVs for all photon plans [21]. All
PTVs were clipped 5mm from the skin surface. The PTV IMC
excluded lung for all photon techniques except tomother-
apy, which was optimised and reported for the whole PTV
IMC, reﬂective of local practice. CTVs were used for proton
plan optimisation and evaluation. The following normal
structures were contoured: heart, left anterior descending
coronary artery (LAD), left lung, right lung, right breast,
thyroid gland, oesophagus and brachial plexus.
Treatment Planning
For each patient, seven plans were generated: wide tan-
gents in voluntary deep inspiratory breath-hold (WT(vDIBH)),
wide tangents in free breathing (WT(FB)), volumetric-
modulated arc therapy in voluntary deep inspiratory breath-
hold (VMAT(vDIBH)), volumetric-modulated arc therapy in
free breathing (VMAT(FB)), tomotherapy in free breathing
(Tomotherapy(FB)), proton beam therapy in voluntary deep
inspiratory breath-hold (PBT(vDIBH)) and proton beam ther-
apy in free breathing (PBT(FB)). Planning was carried out
across two centres. The Royal Marsden NHS Foundation Trust
carried out WT, VMAT and PBT planning and Cambridge
University Trust carried out the tomotherapy planning. Opti-
misation priorities were deﬁned before planning to achieve
consistency between inverse planned semi-automated in-
tensity-modulated radiotherapy techniques. All plans were
for a fractionation schedule of 40 Gy in 15 fractions. The
mandatory target volume constraints for the PTVs and OAR
dose objectives are summarised in Table 1.
WT plans were created manually in the Pinnacle3 v9.10
(Philips, Fitchburg, WI, USA) treatment planning system
(TPS) using opposing wide tangential step-and-shoot
photon beams with a non-divergent posterior ﬁeld edge
modiﬁed to cover the breast or chest wall, IMC and the
inferior part of lymph node levels 1e3. A matched anterior
ﬁeld was used to cover the PTVs of lymph node level 4 and
the superior part of levels 1e3. Heart and lung shielding
was achieved using multileaf collimation. 6 MV photon
beamswere used for most patients. 10MV beamswere used
for the anterior ﬁeld to achieve coverage of nodal volumes
at depth.
VMAT plans were generated using the Pinnacle3 TPS
using Pinnacle’s SmartArc optimisation algorithm with 2
control point spacing. A ‘bowtie’ technique consisting of
two partial arcs, as described by Viren et al. [22], was used.
The two anticlockwise partial arcs each consisted of about
40 (30e50 range) of rotation about the angles used for
Table 1
Target volume and organ at risk dose constraints and objectives
Volume Constraint Objective
PTV WB V38 Gy  90%
PTV nodes (level 1e4 axilla) V32 Gy  90% V36 Gy  90%
PTV IMC V32 Gy  90% V36 Gy  90%
All PTVs Dmax ¼ 110%
Heart V17 Gy  10% Mean heart dose  6 Gy
Left lung V17 Gy  35%
Right lung Mean lung dose  4 Gy
Right breast Mean breast dose  3.5 Gy
PTV, planning target volume; WB, whole breast; IMC, internal mammary chain.
A. Ranger et al. / Clinical Oncology 30 (2018) 346e353348tangential beams. Suitable gantry start and stop angles
were chosen depending on the individual patient anatomy.
Optimisation methods were used to ensure that the ﬁelds
were shaped to the entire PTV. Robustness studies were
used to ensure the VMAT plans exhibited similar robustness
compared with the WT plans (see supplementary material
in Appendix).
Tomotherapy plans were created in the tomotherapy Hi-
ART System v4.2.2, planned using a 5 cm ﬁeld width and a
0.287 pitch. An initialmodulation factor of 1.6was set,which
was increased throughout optimisation with an end plan-
ningmodulation ofw2.6. Ipsilateral lung, contralateral lung,
heart and the lateral part of the contralateral breast were all
directionally blocked for planning. An additional ﬂash vol-
ume was created to ensure adequate coverage of the whole
breast PTV as it moved with the patient’s breathing cycle.
PBT plans were generated using the RayStation v6 TPS
(RaySearch Laboratories, Stockholm, Sweden)using intensity-
modulated pencil beam scanning. A two beam approachwith
one anterior/posterior and one en face beam (45/315) was
used to maximise robustness and improve plan quality [11].
Proton plans were created using the TPS’s robustness opti-
misation algorithm. A range uncertainty correction of 3.5%
and isotropic 5 mm uncertainty for set up errors was incor-
porated. Thesemetricswere derived froma separate planning
study, where eight patients previously treated at our centre
who had regular cone beam computed tomography scans
were re-planned with tangents, VMAT and PBT with ﬁve
different combinations of range and set-up uncertainty pa-
rameters. Estimates of the delivered dose were compared
with the planned dose in order to evaluate the robustness
optimisation parameters that resulted in PBT plans as robust
as photon plans (see supplementary data in Appendix).
Dosimetric Evaluation and Statistical Analysis
In total, 98 plans were created and evaluated. The whole
breast (PTV WB), level 1e4 axilla (PTV nodes) and PTV IMC
were analysed separately to avoid compensation for poor
coverage of the IMC by other PTVs.
Statistical analysis was carried out in Graph Pad Prism
(San Diego, CA, USA) using a one-way ANOVA with all
pairwise comparisons tested using Bonferroni’s multiple
comparisons test, with adjusted P-values  0.05 indicating
statistical signiﬁcance. Target volume coverage and OARdoses were compared between each of the seven tech-
niques. The percentage of plans meeting all target volume
and OAR mandatory constraints was assessed as a measure
of the success of the technique.Results
Figure 1 illustrates dose distributions on the same axial
computed tomography slice in the same patient for the
seven techniques.
The proportion of plans meeting all mandatory con-
straints (pass rate) and the mean target and OAR volume
doses for the 14 patients and seven techniques are pre-
sented in Table 2. All techniques met the mandatory target
volume dose constraints in all patients.Dose Comparisons for Planning Target Volumes
For coverage of the nodal PTVs with 36 Gy (90% pre-
scribed dose), PBT was signiﬁcantly superior to all photon
treatments with the exception of VMAT(vDIBH) for IMC
coverage (Figure 2a). VMAT(vDIBH) achieved signiﬁcantly
greater coverage of the IMC with 36 Gy in comparison to all
other photon therapies. All arc therapy techniques achieved
greater coverage of the nodal PTVs with 36 Gy when
compared with the WT techniques (Figure 2b) but there
was no statistically signiﬁcant difference between the arc
therapy technique used.Dose Comparisons for Organs at Risk
OAR doses varied considerably between techniques. The
MHD was signiﬁcantly reduced using breath-hold as
compared with FB for both WT and VMAT photon tech-
niques (Figure 2c). There was no signiﬁcant difference in
MHD between WT and VMAT in vDIBH or WT and VMAT in
FB. Tomotherapy and WT(FB) resulted in a signiﬁcant in-
crease in MHD when compared with all other photon
techniques. PBT signiﬁcantly reduced MHD compared with
each of the photon techniques. However, there was no
statistically signiﬁcant improvement in MHD when PBT
was planned in vDIBH as compared with FB. Both heart
V17Gy and maximum LAD dose were statistically
Fig 1. Images of the same computed tomography slice in the same patient showing the dose distribution achieved by each of the seven
radiotherapy planning techniques. The top row displays free breathing plans: (A) wide tangents in free breathing (WT(FB)), (B) volumetric-
modulated arc therapy in free breathing (VMAT(FB)), (C) proton beam therapy in free breathing (PBT(FB)), (D) tomotherapy in free breathing
(tomotherapy(FB)). The bottom row displays breath-hold scans: (E) wide tangents in voluntary deep inspiratory breath-hold (WT(vDIBH)), (F)
volumetric-modulated arc therapy in voluntary deep inspiratory breath-hold (VMAT(vDIBH)), (G) proton beam therapy in voluntary deep
inspiratory breath-hold (PBT (vDIBH)). The structures outlined in yellow are the whole breast and internal mammary chain clinical target
volumes.
A. Ranger et al. / Clinical Oncology 30 (2018) 346e353 349signiﬁcantly lower for photon techniques in breath-hold
and tomotherapy.
Ipsilateral lung dose (lung V17 Gy) was signiﬁcantly
reduced using breath-hold as compared with FB for the WT
technique and VMAT technique (Figure 2d). There was also
no signiﬁcant reduction in ipsilateral lung dose for PBT in
vDIBH compared with FB. However, PBT resulted in signif-
icantly lower ipsilateral lung doses when compared with all
photon therapies.
The contralateral lung dose was within constraints for all
patients using all techniques (Table 2). However, tomo-
therapy resulted in a statistically higher mean contralateral
lung dose when compared with other photon techniques
(Figure 2e). Contralateral breast doses were also within the
constraint set for all patients using all modalities (Table 2).
However, PBT (in vDIBH and FB) resulted in a signiﬁcant
reduction in contralateral breast dose when compared with
all photon techniques (Figure 2f).Discussion
This study, comparing seven techniques for locoregional
breast cancer radiotherapy, including irradiation of the IMC,
shows that it is possible to achieve adequate target volume
coverage using all techniques tested, albeit with varying
doses to OARs.
The simple WT technique with vDIBH met mandatory
target volume constraints with low doses to the OARs for all
14 patients studied. Coverage of the nodal target volumes
with 80% of the prescribed dose (32 Gy) is consistent with
the target volume coverage achieved in the randomised
controlled trials demonstrating the beneﬁts of pan-regional
lymph node radiotherapy. For example, in the MA20 study,which showed a disease-free survival beneﬁt with regional
lymph node radiotherapy (including the IMC), Whelan et al.
[3] speciﬁed that the IMC should be covered with the 80%
isodose, whereas in the Danish Breast Cancer Group (DBCG)
IMN study, which showed an overall survival beneﬁt from
inclusion of the IMC in the target volume, it was speciﬁed
that 90% of the IMC CTV should be covered by the 90%
isodose [4]. The WT technique achieves lower MHDs than
those previously published for three-dimensional
conformal radiotherapy to the IMC [12e15] by eliminating
the use of an anterior ﬁeld, in contrast to the matched
photon-electron ﬁeld technique, for example.
Our results are consistent with previous data showing
that arc therapies and PBToffer improved coverage of target
volumes compared with ﬁeld-based treatments. However,
arc therapies in FB struggle to achieve coverage of the IMC
with 90% of the prescribed dose while maintaining a low
MHD [12,13,15,23]. VMAT(FB) and tomotherapy techniques
met all planning constraints and both techniques per-
formed relatively well on heart V17Gy and left lung V17Gy, but
less well on MHD. The nature of tomotherapy’s delivery
resulted in the largest mean heart and contralateral lung
doses of the techniques tested. This, combined with the
inability to deliver tomotherapy in breath-hold, poses an
ongoing limitation of the technique. Nonetheless, for pa-
tients who are unable to tolerate breath-hold it is useful to
note that both tomotherapy and VMAT(FB) reduced heart
V17 Gy and LAD doses when compared with WT(FB) due to
their ability to shape higher isodoses away from the ante-
rior aspect of the heart. Although the MHD is the only
parameter on which a dose-effect relationship has been
reported [7], it is conceivable that this is a surrogate for
doses to the anterior part of the heart (which are more
speciﬁcally reﬂected in the heart V17 Gy and LAD doses), in
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A. Ranger et al. / Clinical Oncology 30 (2018) 346e353350which case the risk of late cardiac events associated with a
plan that meets the heart V17 Gy constraint but not the MHD
constraint may not be as high as predicted on existing data
[7]. The decision over how to balance target volume
coverage versus MHD will ultimately come down to the
balance of clinical risks as well as the feasibility of deliv-
ering a particular technique in each case.
For VMAT and vDIBH, Osman et al. [14] have previously
shown a reduction in MHD with the combination of partial
arc VMAT and vDIBH as compared with three-dimensional
conformal radiotherapy in vDIBH (4.1 Gy versus 5.0 Gy).
Our data show that even lower MHDs can be achieved
(VMAT(vDIBH) ¼ 2.6 Gy  1.0 standard deviation;
WT(vDIBH) ¼ 2.5 Gy  1.2 standard deviation) but this
difference is likely to be explained by the combination of
the higher target volume coverage dose constraint
(V95% 95%) together with the increased dose prescription
(42.56 Gy in 16 fractions) used in the previous study.
PBT is superior to photon therapies, both for target vol-
ume coverage and OAR dose, as previously shown
[12,15,24]. There seems to be no signiﬁcant beneﬁt in
attempting to treat patients with PBT in vDIBH, consistent
with ﬁndings from recent studies investigating this com-
bination [25,26]. PBT is the only therapy capable of deliv-
ering a mean contralateral breast dose <1 Gy. This is
probably important for young patients (<40 years) inwhom
any dose >1 Gy increases the risk of secondary malignancy
[27,28]. We have attempted to address the issue of the
robustness of PBT plans in this study but it may be neces-
sary to further increase this level of robustness optimisa-
tion, which would have a corresponding effect on OAR dose.
The effect of even minor discrepancies in tissue density
along the path of the proton and the potential effect of these
on dose deposition remain of concern. For example, the
position of a proton beam directly adjacent to the LAD raises
the possibility that, if the end of the Bragg peak were to be
underestimated by a matter of millimetres, the full dose
could be deposited in this critical structure [29,30]. This risk
could be reduced by carrying out daily cone beam
computed tomography scanning with online correction to
decrease inter-fraction positional uncertainty. Additionally,
although this planning study shows no dosimetric advan-
tage of using breath-hold in the context of protons, the use
of breath-hold could help to reduce intra-fraction motion.
By using a seven-way comparison of techniques we have
shown that, for photon techniques, moving the heart out of
the way (using breath-hold) is a more effective strategy for
reducing heart dose than purely shaping the dose (using arc
therapy). Recent modelling data published by the Early
Breast Cancer Collaborative Group [31] suggest that the
absolute increase in cardiac mortality associated with a
MHD of 4 Gy is extremely low (0.3% for a non-smoker before
the age of 80 years). In this study, MHDs <4 Gy were ach-
ieved by both WT(vDIBH) and VMAT(vDIBH), establishing
these techniques as acceptable options for heart-sparing
IMC radiotherapy. It is possible to reduce MHDs to below
4 Gy with arc therapies in FB, but this may be at the cost of
reduced nodal target volume coverage. The additional
dosimetric beneﬁts offered by PBT are small and would be
Fig 2. Differences in mean target volume coverage and organ at risk doses between techniques (Technique A, Technique B). WT(vDIBH), wide
tangents in voluntary deep inspiratory breath-hold; WT(FB), wide tangents in free breathing; VMAT(vDIBH), volumetric-modulated arc therapy
in voluntary deep inspiratory breath-hold; VMAT(FB), volumetric-modulated arc therapy in free breathing; TT(FB), tomotherapy in free
breathing; PBT(vDIBH), proton beam therapy in voluntary deep inspiratory breath-hold; PBT(FB), proton beam therapy in free breathing.
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toxicity. For example, for a non-smoker with no additional
cardiac risk factors, the delivery of pan-regional lymph node
radiotherapy using WT or VMAT in vDIBH would deliver on
average 2 Gy greater MHD than using PBT, which would
result in an absolute increase in cardiac mortality of less
than 0.15% [31]. However, there will be individual patients
with anatomical variations (e.g. those with pectus excava-
tum) in whom PBT will achieve a clinically signiﬁcantly
greater reduction in MHD compared with the optimal
photon technique (VMAT in vDIBH).
This study was limited by differences in radiotherapy
planning between individuals and across two sites. Although
optimisation parameters were deﬁned before planning and
mandatory dose constraint coverage of target volumes was
prioritised for all techniques, inter-planner variation be-
tween the three dosimetrists and individual interpretation of
the dose objectives resulted in variations in target volumecoverage with higher dose, MHD and LAD dose. The gen-
eralisability of the results was further limited by the small
sample size used in this study. The study also provided no
data regarding the feasibility of implementing the tech-
niques tested. It is possible that the resource implications
associated with implementing VMAT(vDIBH) for all patients
requiring IMC radiotherapy could slow or prevent the
implementation of IMC radiotherapy in resource-limited
healthcare settings. By comparison, the WT(vDIBH) tech-
nique could be implemented in many radiotherapy centres
with relatively little need for additional equipment or
training (provided a dose of 32 Gy to the locoregional nodes
is deemed acceptable). The HeartSpare Plus clinical phase II
study is currently testing the feasibility, resource impact and
acute toxicities of WT(vDIBH) versus VMAT techniques.
Ultimately, one technique will not be appropriate for all
patients. This study presented a range of possible tech-
niques for treating the IMC that can be tailored to the
A. Ranger et al. / Clinical Oncology 30 (2018) 346e353352individual based on factors such as risk of recurrence,
anatomy and ability to tolerate breath-hold.Conclusion
In this dosimetry study, simple WT radiotherapy deliv-
ered in vDIBH achieved satisfactory coverage of the IMC
while meeting heart and lung dose constraints. However,
where higher isodose coverage is required, VMAT(vDIBH) is
the optimal photon technique. The lowest OAR doses are
achieved by PBT, in which the use of vDIBH does not
improve dose statistics. Ideally centres will have access to
more than one technique in order to select the optimal
solution for individual patients.Acknowledgements
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